Sep 06, 2023 / 05:50PM GMT
Peter Verdult - Citigroup Inc., Research Division - MD
(technical difficulty) today. Now some of you will have an older version of the itinerary and realize that I don't have Bill Sibold sitting next to me. But rather than just canceling on us after Bill's departure last week, (inaudible) stepped up and have given us 2 speakers, really topical. Brian Foard, who did run Dupixent and some of you met him at the immunology session last year. He's now the Head of Specialty Care North America and Country Head for the U.S. and Kim Tutwiler, Head of RSV Development. So very timely to have both of you here, and thank you very much for just pulling out and coming.
So I'll try and make this as interactive as possible. Those that know me will know I always say this here to moderate, not monopolize. If any of you want to ask questions, shout out, stick your hand up or actually have been told in the back, wait for the mic before you ask your questions. But before we do that, I think Brian wants to make some opening remarks, and then we'll go into some Q&A. So Brian, Kim, thank you. Over to you.
Sanofi SA at Citi BioPharma Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers